abstract |
The present invention relates to compounds of the formula (I) (see Formula) wherein Y, Y1, R1, R2, R3 and R4 are defined in the Brief Description of the Invention; capable of inhibiting the activity of BCR-ABL1 and its mutants. The invention further provides a process for the preparation of the compounds of the invention, pharmaceutical compositions comprising such compounds, and methods for using these compounds in the treatment of cancers. |